bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
Business Wire•22/07/2026•08:08 ET
2
Whiz Insights
bioAffinity Technologies and Pictor(®), Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide
Get started
Create a free account to read the full story.